Combinatorial Efficacy Achieved Through Two-Point Blockade within a Signaling Pathway - A Chemical Genetic Approach

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8930-8938

  Fan, Qi Wen ^a,b   Specht, Kimberly Musa ^a,b   Zhang, Chao ^a,b   Goldenberg, Dmitriy D ^a,b   Shokat, Kevan M ^a,b   Weiss, William A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHYLPYRAZOLOPYRIMIDINE DERIVATIVE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 5 (4 METHYLPHENYL) 7 (T BUTYL)PYRAZOLO D 3,4 PYRIMIDINE; 4-AMINO-5-(4-METHYLPHENYL)-7-(T-BUTYL)PYRAZOLO-D-3,4-PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; NAPHTHALENE DERIVATIVE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN V ERBB; PYRAZOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLELE; ALLOGRAFT; ANIMAL; ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER THERAPY; CELL DIVISION; CELL STRAIN 3T3; CHEMICAL GENETIC APPROACH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYMOLOGY; FEMALE; FIBROBLAST; GENETIC TRANSDUCTION; GENETIC TRANSFORMATION; GENETICS; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; NAPHTHALENES; NIH 3T3 CELLS; ONCOGENE PROTEINS V-ERBB; PYRAZOLES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0346690261     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell, 1: 31-36, 2002.
2. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 351: 95-105, 2000.
3. Drevs, J., Medinger, M., Schmidt-Gersbach, C., Weber, R., and Unger, C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets, 4: 113-121, 2003.
4. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. The protein kinase complement of the human genome. Science (Wash. DC), 298: 1912-1934, 2002.
5. Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., and Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med., 6: 1024-1028, 2000.
6. Ritland, S. R., Gendler, S. J., Burgart, L. J., Fry, D. W., Nelson, J. M., Bridges, A. J., Andress, L., and Karnes, W. E., Jr. Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury. Cancer Res., 60: 4678-4681, 2000.
7. Roberts, R. B., Min, L., Washington, M. K., Olsen, S. J., Settle, S. H., Coffey, R. J., and Threadgill, D. W. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA, 99: 1521-1526, 2002.
8. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (Lond.), 307: 521-527, 1984.
9. Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., and Shokat, K. M. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol., 6: 671-678, 1999.
10. Fan, Q. W., Zhang, C., Shokat, K. M., and Weiss, W. A. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr. Biol., 12: 1386-1394, 2002.
11. Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., Wood, J. L., Morgan, D. O., and Shokat, K. M. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (Lond.), 407: 395-401, 2000.
12. Gillespie, P. G., Gillespie, S. K., Mercer, J. A., Shah, K., and Shokat, K. M. Engineering of the myosin-iβ nucleotide-binding pocket to create selective sensitivity to N(6)-modified ADP analogs. J. Biol. Chem., 274: 31373-31381, 1999.
13. Liu, Y., Witucki, L. A., Shah, K., Bishop, A. C., and Shokat, K. M. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities. Biochemistry, 39: 14400-14408, 2000.
14. Habelhah, H., Shah, K., Huang, L., Burlingame, A. L., Shokat, K. M., and Ronai, Z. Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J. Biol. Chem., 276: 18090-18095, 2001.
15. Wang, H., Shimizu, E., Tang, Y. P., Cho, M., Kyin, M., Zuo, W., Robinson, D. A., Alaimo, P. J., Zhang, C., Morimoto, H., Zhuo, M., Feng, R., Shokat, K. M., and Tsien, J. Z. Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc. Natl. Acad. Sci. USA, 100: 4287-4292, 2003.
16. Eblen, S. T., Kumar, N. V., Shah, K., Henderson, M. J., Watts, C. K., Shokat, K. M., and Weber, M. J. Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J. Biol. Chem., 278: 14926-14935, 2003.
17. Abeliovich, H., Zhang, C., Dunn, W. A., Jr., Shokat, K. M., and Klionsky, D. J. Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol. Biol. Cell, 14: 477-490, 2003.
18. Niswender, C. M., Ishihara, R. W., Judge, L. M., Zhang, C., Shokat, K. M., and McKnight, G. S. Protein engineering of protein kinase A catalytic subunits results in the acquisition of novel inhibitor sensitivity. J. Biol. Chem., 277: 28916-28922, 2002.
19. Holt, J. R., Gillespie, S. K., Provance, D. W., Shah, K., Shokat, K. M., Corey, D. P., Mercer, J. A., and Gillespie, P. G. A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell, 108: 371-381, 2002.
20. Carroll, A. S., Bishop, A. C., DeRisi, J. L., Shokat, K. M., and O'Shea, E. K. Chemical inhibition of the Pho85 cyclin-dependent kinase reveals a role in the environmental stress response. Proc. Natl. Acad. Sci. USA, 98: 12578-12583, 2001.
21. Buzko, O., and Shokat, K. M. A kinase sequence database: sequence alignments and family assignment. Bioinformatics, 18: 1274-1275, 2002.
22. Specht, K. M., and Shokat, K. M. The emerging power of chemical genetics. Curr. Opin. Cell Biol., 14: 155-159, 2002.
23. Shokat, K., and Velleca, M. Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Discov. Today, 7: 872-879, 2002.
24. Shogren-Knaak, M. A., Alaimo, P. J., and Shokat, K. M. Recent advances in chemical approaches to the study of biological systems. Annu. Rev. Cell Dev. Biol., 17: 405-433, 2001.
25. Alaimo, P. J., Shogren-Knaak, M. A., and Shokat, K. M. Chemical genetic approaches for the elucidation of signaling pathways. Curr. Opin. Chem. Biol., 5: 360-367, 2001.
26. Bishop, A. C., Buzko, O., and Shokat, K. M. Magic bullets for protein kinases. Trends Cell Biol., 11: 167-172, 2001.
27. Bishop, A., Buzko, O., Heyeck-Dumas, S., Jung, I., Kraybill, B., Liu, Y., Shah. K., Ulrich, S., Witucki, L., Yang, F., Zhang, C., and Shokat, K. M. Unnatural ligands for engineered proteins: new tools for chemical genetics. Annu. Rev. Biophys. Biomol. Struct., 29: 577-606, 2000.
28. Bishop, A. C., Shah, K., Liu, Y., Witucki, L., Kung, C., and Shokat, K. M. Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol., 8: 257-266, 1998.
29. Bishop, A. C., and Shokat, K. M. Acquisition of inhibitor-sensitive protein kinases through protein design. Pharmacol. Ther., 82: 337-346, 1999.
30. Schatzman, R. C., Evan, G. I., Privalsky, M. L., and Bishop, J. M. Orientation of the v-erb-B gene product in the plasma membrane. Mol. Cell. Biol., 6: 1329-1333, 1986.
31. Weiss, W. A., Burns, M. J., Hackett, C., Aldape, K., Hill, J. R., Kuriyama, H., Kuriyama, N., Milshteyn, N., Roberts, T., Wendland, M. F., DePinho, R., and Israel, M. A. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res., 63: 1589-1595, 2003.
32. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 82: 241-250, 1999.
33. Hacker, G. The morphology of apoptosis. Cell Tissue Res., 301: 5-17, 2000.
34. Vivanco, I., and Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.
35. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (Lond.), 313: 144-147, 1985.
36. Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., and Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA, 89: 2965-2969, 1992.
37. Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., and Collins, V. P. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res., 51: 2164-2172, 1991.
38. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA, 91: 7727-7731, 1994.
39. Mishima, K., Johns, T. G., Luwor, R. B., Scott, A. M., Stockert, E., Jungbluth, A. A., Ji, X. D., Suvama, P., Voland, J. R., Old, L. J., Huang, H. J., and Cavenee, W. K. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res., 61: 5349-5354, 2001.
40. Luwor, R. B., Johns, T. G., Murone, C., Huang, H. J., Cavenee, W. K., Ritter, G., Old, L. J., Burgess, A. W., and Scott, A. M. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res., 61: 5355-5361, 2001.
41. Narita, Y., Nagane, M., Mishima, K., Huang, H. J., Fumari, F. B., and Cavenee, W. K. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res., 62: 6764-6769, 2002.
42. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Wash. DC), 278: 687-689, 1997.
43. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
44. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Wash. DC), 282: 1318-1321, 1998.
45. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond.), 378: 785-789, 1995.
46. Biggs, W. H., 3rd, Meisenhelder, J., Hunter, T., Cavenee, W. K., and Arden, K. C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA, 96: 7421-7426, 1999.
47. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
48. Kwiatkowski, D. J. Tuberous Sclerosis: from Tubers to mTOR. Ann. Hum. Genet, 67: 87-96, 2003.